JP2025515358A - アミノ酸の組合せを有する医薬組成物および栄養補助組成物ならびに組織への脂質蓄積を特徴とする疾患におけるその使用 - Google Patents

アミノ酸の組合せを有する医薬組成物および栄養補助組成物ならびに組織への脂質蓄積を特徴とする疾患におけるその使用 Download PDF

Info

Publication number
JP2025515358A
JP2025515358A JP2024563636A JP2024563636A JP2025515358A JP 2025515358 A JP2025515358 A JP 2025515358A JP 2024563636 A JP2024563636 A JP 2024563636A JP 2024563636 A JP2024563636 A JP 2024563636A JP 2025515358 A JP2025515358 A JP 2025515358A
Authority
JP
Japan
Prior art keywords
pharma
solvate
acceptable salt
therapeutically
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024563636A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025515358A5 (cg-RX-API-DMAC7.html
Inventor
バス プリオール,ジョゼップ マリア デル
ミロ,ザビエル エスコテ
バスケス,セルジオ ケサダ
レモス,ホセ マヌエル フェルナンデス-リアル
ペルザックス,ジョルディ マイネリス
ルケ,フリオ カルロス ボーダン
パロウ,アントニ カイマリ
リャビネス,フランチェスク プイグロス
ノバウ,アナ カステルス
Original Assignee
ファンダシオ ユーレキャット
ファンダシオ インスティチュート デ インベスティゲーシオ バイオメディカ デ ジローナ ドクター ジョゼップ トゥルエータ
コンソルシオ セントロ デ インベスティゲーシオン バイオメディカ エン レッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファンダシオ ユーレキャット, ファンダシオ インスティチュート デ インベスティゲーシオ バイオメディカ デ ジローナ ドクター ジョゼップ トゥルエータ, コンソルシオ セントロ デ インベスティゲーシオン バイオメディカ エン レッド filed Critical ファンダシオ ユーレキャット
Publication of JP2025515358A publication Critical patent/JP2025515358A/ja
Publication of JP2025515358A5 publication Critical patent/JP2025515358A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
JP2024563636A 2022-04-25 2023-04-25 アミノ酸の組合せを有する医薬組成物および栄養補助組成物ならびに組織への脂質蓄積を特徴とする疾患におけるその使用 Pending JP2025515358A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22382390 2022-04-25
EP22382390.7 2022-04-25
PCT/EP2023/060827 WO2023208944A1 (en) 2022-04-25 2023-04-25 Pharmaceutical and nutraceutical compositions with a combination of amino acids and its use in diseases characterized by lipid accumulation in tissues

Publications (2)

Publication Number Publication Date
JP2025515358A true JP2025515358A (ja) 2025-05-14
JP2025515358A5 JP2025515358A5 (cg-RX-API-DMAC7.html) 2026-05-08

Family

ID=81579974

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024563636A Pending JP2025515358A (ja) 2022-04-25 2023-04-25 アミノ酸の組合せを有する医薬組成物および栄養補助組成物ならびに組織への脂質蓄積を特徴とする疾患におけるその使用

Country Status (7)

Country Link
US (1) US20250268855A1 (cg-RX-API-DMAC7.html)
EP (1) EP4514147A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025515358A (cg-RX-API-DMAC7.html)
CN (1) CN119343061A (cg-RX-API-DMAC7.html)
CA (1) CA3249636A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024013203A (cg-RX-API-DMAC7.html)
WO (1) WO2023208944A1 (cg-RX-API-DMAC7.html)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190146A1 (ar) * 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
US11246846B2 (en) * 2017-10-23 2022-02-15 Michael S. Tempesta Trisodium citrate compositions having enhanced uptake across digestive mucosa

Also Published As

Publication number Publication date
EP4514147A1 (en) 2025-03-05
CN119343061A (zh) 2025-01-21
MX2024013203A (es) 2025-02-10
CA3249636A1 (en) 2023-11-02
WO2023208944A1 (en) 2023-11-02
US20250268855A1 (en) 2025-08-28

Similar Documents

Publication Publication Date Title
Wang et al. Targeting the gut microbiota with resveratrol: a demonstration of novel evidence for the management of hepatic steatosis
Williams et al. New advances in molecular mechanisms and emerging therapeutic targets in alcoholic liver diseases
Reggiori et al. Autophagy: more than a nonselective pathway
Zhang et al. Taraxacum officinale-derived exosome-like nanovesicles modulate gut metabolites to prevent intermittent hypoxia-induced hypertension
JP5176964B2 (ja) ジペプチジルペプチダーゼiv阻害剤
US20240238232A1 (en) Compositions and methods for the reduction or treatment of insulin resistance and metabolic conditions
JP5096173B2 (ja) 経口摂取用関節リウマチ抑制剤
KR20170116231A (ko) 주사 또는 홍안 관련 피부 질환의 치료를 위한, 베르베린 또는 그의 유사체를 함유하는 조성물
EP3548058A1 (en) Compositions comprising peptide wkdeagkplvk
US20170326201A1 (en) Novel fat accumulation inhibitory peptide and pharmaceutical composition for preventing or treating obesity containing the same
CN117919232B (zh) 吲哚丙酸在治疗肝硬化以及免疫性肝损伤的应用
CN110099690B (zh) 适于非酒精性脂肪性肝病和/或非酒精性脂肪性肝炎和/或肝脂肪变性的治疗的复方制剂
Zhang et al. Conjugated linoleic acid (CLA) reduces intestinal fatty acid uptake and chylomicron formation in HFD-fed mice associated with the inhibition of DHHC7-mediated CD36 palmitoylation and the downstream ERK pathway
Chiang et al. Lipolysis-stimulating peptide-VHVV ameliorates high fat diet induced hepatocyte apoptosis and fibrosis
Ganai et al. Regression of fibrosis/cirrhosis by Glycine propionyl-l-carnitine treatment in d-Galactosamine induced chronic liver damage
CN115006532A (zh) 蛋白酶体抑制剂的应用
Zhu et al. Effects of Celastrus orbiculatus on Epithelial Mesenchymal Transition in Gastric Mucosal Epithelial Cells by Inhibiting Lgr 5 Expression from Rats with Gastric Precancerous Lesions
US20250268855A1 (en) Pharmaceutical and nutraceutical compositions with a combination of amino acids and its use in diseases characterized by lipid accumulation in tissues
CN103446166B (zh) 肝功能改善剂
EP4208160A1 (en) Ionic liquid formulations for treating diabetes
WO2024178621A1 (en) Use of compounds in preventing and/or treating obesity or nafld
KR20110128782A (ko) 소화관에서 펩티드의 완전성을 유지하기 위한 프로테아제 억제제로서의 담즙산 및 비구아니드
JP7291917B2 (ja) トリペプチドrprを含有する抗肥満薬並びに健康食品
US20260108588A1 (en) A complex comprising a alpha-lactalbumin and a fatty acid or lipid for use in the treatment or prevention of cancer
DK2878306T3 (en) MODIFIED PEPTIDE, CB RECEPTOR LIGAND, KIT, IN VITRO PROCEDURE FOR EVALUATION OF CB RECEPTOR BINDINGS, APPLICATIONS, PHARMACEUTICAL COMPOSITION FOR MODULATING CBRECEPTOR ACTIVITY

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260424

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260424